<DOC>
	<DOCNO>NCT00734669</DOCNO>
	<brief_summary>The aim study establish risk frequency non-symptomatic hypoglycemia type 2 diabetes previous therapy glibenclamide . Participants monitor via continuous glucose monitoring system standardized clinical setting day night time , implement meal exercise moderate intensity perform postprandial state .</brief_summary>
	<brief_title>Risk Hypoglycemia Type 2 Diabetes</brief_title>
	<detailed_description>The day-to-day change blood glucose associate frequency vascular complication quality life diabetic patient . In study frequency hypoglycemic event combination postprandial hyperglycemia type 2 diabetic patient oral insulinotropic therapy observe . Using sophisticated technology probability type 2 diabetic patient glibenclamide experience hypoglycemic episode register . Hypoglycemia prone cardiovascular complication type 2 diabetic patient due concomitant dysregulation blood flow . With standardized test meal follow exercise clinical set hormonal counterregulation cardiovascular parameter associate hypoglycemia identify . The acute effect different condition exercise single dose either glibenclamide placebo follow day total three-day observation period . Thus evaluate frequency risk factor associate hypoglycemia meal-related hyperglycemia type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Type 2 diabetes glibenclamide without Glycated hemoglobin â‰¤ 7.5 % Stable dosage three week HbA1c &gt; 7.5 % Fasting Cpeptide normal Concurrent infectious disease Pregnancy Malignant disease Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hypoglycemia</keyword>
</DOC>